Net sales of diabetes medicines of Novo Nordisk in Greater China 2019, by product

In 2019, the Danish pharmaceutical company Novo Nordisk reported that its long-acting insulin medication Levemir® had generated about 972 million Danish kroner in Greater China. After one year of launching its another long-acting insulin product Tresiba® in China, the firm recorded a significant sales growth of the medication in 2019.

Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2019, by key product

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until September 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2020

Region

China, Taiwan, Hong Kong

Survey time period

2019

Supplementary notes

Note: 1 Danish kroner equals approximately 0.15 U.S. dollars and 0.13 euros (as of May 2020).

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Diabetes in China"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.